ArticleThe pharmacogenomics journal2013
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.
Article in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.The pharmacogenomics journal · 2017Pooled it
- Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ-1a Biologics.Clinical and translational science · 2025Trial
- Interleukin 17F level and interferon β response in patients with multiple sclerosis.JAMA neurology · 2013Trial
- Beta Interferon 1a and Laquinimod Differentially Affect Coagulation-Related Gene Expression in Multiple Sclerosis Patients: Implications for Clinical Efficacy and Side Effects.International journal of molecular sciences · 2025Article
- Cryptococcosis, tuberculosis, and a kidney cancer fail to fit the atherosclerosis paradigm for foam cell lipid content.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis.Journal of lipid research · 2020Article
- Lipid and Lipoprotein Metabolism in Microglia.Frontiers in physiology · 2020Review
- The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.Frontiers in immunology · 2020Review
- Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.Nature reviews. Drug discovery · 2019Review
- Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific.PLoS pathogens · 2018Article
- A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients.Clinical and experimental immunology · 2018Article
- Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study.Frontiers in immunology · 2018Article
- TLDc proteins: new players in the oxidative stress response and neurological disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2017Review
- Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis.Scientific reports · 2017Article
- Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.Immunology and cell biology · 2016Article
- Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFNβ-treated and untreated multiple sclerosis patients.Experimental and therapeutic medicine · 2016Article
- Redox Activation of the Universally Conserved ATPase YchF by Thioredoxin 1.Antioxidants & redox signaling · 2016Article
- Article
- Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.BMC neurology · 2015Article
- Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon beta (IFNβ) reduces disease burden in relapsing-remitting multiple sclerosis (MS) patients. In this study, IFNβ-1b-treated MS patient gene expression profiles and biological knowledgebases were integrated to study IFNβ's pleiotropic mechanisms of action. Genes involved in immune regulation, mitochondrial fatty acid metabolism and antioxidant activity were discovered. Plausible mediators of neuronal preservation included NRF2, downregulation of OLA1, an antioxidant suppressor, and the antioxidant gene ND6, implicated in optic neuropathy and MS-like lesions. Network analysis highlighted IKBKE, which likely has a role in both viral response and energy metabolism. A comparative analysis of therapy-naive MS- and IFNβ-associated gene expression suggests an IFNβ insufficiency in MS. We observed more gene expression changes in long-term treatment than during acute dosing. These distinct short- and long-term effects were driven by different transcription factors. Multi-gene biomarker signatures of IFNβ treatment effects were developed and subsequently confirmed in independent IFNβ-1b-treated MS studies, but not in glatiramer acetate-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.